Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of specific equity plan transactions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported. The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs) on November 14, 2013, at a price of $52.13 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c) regarding the following transactions:
- Dr M M Slaoui: 13 ADSs
- Dr K Slaoui (Connected Person): 11 ADSs
- Mr W C Louv: 19 ADSs
- Mrs D P Connelly: 2 ADSs
Investor Verification Checklist
- Verify the impact of the 401K plan revaluation on total insider holdings.
- Confirm the ADS price of $52.13 against market data for November 14, 2013.
- Note that this filing does not replace or update quarterly or annual financial reports.